Oxurion

Oxurion Current Assets

The Current Assets of Oxurion (OXUR.BR) as of Oct 15, 2026 is 3.59 M EUR. In the previous year, Current Assets was 2.74 M EUR — a change of 30.84% (higher).

Current Assets

3.59 MEUR

YoY

30.84%

Last updated:

Current Assets of Oxurion is 2024 3.59 M EUR. Current Assets of Oxurion was 2023 2.74 M EUR. It decreases by 30.84% higher compared to the previous year.

The Oxurion Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2017
124.28 M EUR
Jan 1, 2018
91.09 M EUR
Jan 1, 2019
57.02 M EUR
Jan 1, 2020
27.05 M EUR
Jan 1, 2021
13.41 M EUR
Jan 1, 2022
7.11 M EUR
Jan 1, 2023
2.74 M EUR
Jan 1, 2024
3.59 M EUR
The Oxurion Current Assets history
YEARCurrent AssetsYoY
3.59 MEUR+30.84%
2.74 MEUR-61.44%
7.11 MEUR-47.01%
13.41 MEUR-50.44%
27.05 MEUR-52.55%
57.02 MEUR-37.41%
91.09 MEUR-26.71%
124.28 MEUR+35.92%
91.44 MEUR-21.65%
116.70 MEUR-21.78%
149.20 MEUR-22.17%
191.70 MEUR+22.73%
156.20 MEUR+77.90%
87.80 MEUR-22.64%
113.50 MEUR+41.70%
80.10 MEUR+65.84%
48.30 MEUR+40.82%
34.30 MEUR+226.67%
10.50 MEUR-12.50%
12.00 MEUR-8.40%
13.10 MEUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Oxurion Stock analysis

What does Oxurion do? Oxurion NV is a biotechnology company based in Heverlee, Belgium, operating within the healthcare sector. The company has 77 employees and went public on July 7, 2006. Oxurion focuses on developing and commercializing treatments for vitreoretinal diseases. Its lead product, JETREA (ocriplasmin), received U.S. Food and Drug Administration approval for the treatment of symptomatic vitreomacular adhesion (VMA) and was launched in January 2013. The company collaborates with Alcon, a division of Novartis, for the commercialization of JETREA outside the United States. In Europe, JETREA is approved for the treatment of vitreomacular traction (VMT), including cases associated with macular holes of 400 microns or smaller, with launches in the United Kingdom and Germany. Oxurion is also researching anti-PIGF (Placental Growth Factor), known as TB-403, for potential use in ophthalmic and oncology treatments. The company maintains operations in Belgium, the United States, and Ireland, with its headquarters in Heverlee, Vlaams-Brabant. Oxurion's website is www.oxurion.com. Oxurion is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Oxurion stock

Current Assets of Oxurion is 3.59 M EUR in 2024.

Current Assets of Oxurion changed from 2.74 M EUR to 3.59 M EUR, representing a 30.84% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Current Assets Oxurion since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's Oxurion historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Oxurion

All Key Metrics — Oxurion